
Cancer
HealthScientists re-engineer a patient’s own T cells to target and destroy cancer cells
A new HSP-CAR30 CAR-T therapy is delivering lasting remissions in patients with refractory lymphoma, showing promise in early trials.
Mac Oliveau

A new HSP-CAR30 CAR-T therapy is delivering lasting remissions in patients with refractory lymphoma, showing promise in early trials.
Mac Oliveau